--- title: "U.S. stock market midday update: Pyxis Oncology up 12.37%, soaring 135% in six months, is there a surge driven by funds without good news?" type: "News" locale: "en" url: "https://longbridge.com/en/news/295697227.md" description: "Pyxis Oncology rose 12.37%; AbbVie fell 0.84%, with a transaction volume of USD 452 million; Gilead Sciences fell 0.02%, with a transaction volume of USD 371 million; Amgen rose 0.39%, with a transaction volume of USD 339 million; Fortress Biotech fell 0.79%, with a market value of USD 133.2 billion" datetime: "2026-08-12T18:13:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295697227.md) - [en](https://longbridge.com/en/news/295697227.md) - [zh-HK](https://longbridge.com/zh-HK/news/295697227.md) generator: "portal-rs" --- # U.S. stock market midday update: Pyxis Oncology up 12.37%, soaring 135% in six months, is there a surge driven by funds without good news? **U.S. Stock Market Midday Update** Pyxis Oncology, up 12.37%, with a six-month increase of 135.19%, has no significant news recently. Trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie down 0.84%. Based on recent key news: 1. On August 11, AbbVie announced the acquisition of Apogee for $135.11 per share, totaling approximately $10.9 billion. This move aims to expand its immunology product portfolio and enhance global patient coverage, impacting the stock price. 2. On August 12, BNP Paribas raised AbbVie's target price from $218 to $247, reflecting market confidence in its future growth, despite short-term stock price fluctuations. 3. On August 10, AbbVie's high price-to-earnings ratio raised valuation concerns among some investors, but analysts predict a future P/E ratio of about 18, indicating long-term investment value. The pharmaceutical industry shows significant growth potential, with noticeable capital inflows. Gilead Sciences down 0.02%. Based on recent key news: 1. On August 11, Gilead Sciences entered into an exclusive licensing agreement with MacroGenics, triggering a $10 million payment. This move enhances Gilead's R&D capabilities in cancer treatment, driving the stock price up. 2. On August 4, Gilead Sciences reported quarterly sales of $7.803 billion, exceeding analyst expectations. Strong financial data boosted market confidence, leading to a stock price increase. 3. On August 11, Tango Therapeutics reported the end of its collaboration with Gilead, resulting in a stock price decline. The termination of the partnership may affect Gilead's future revenue expectations. The biopharmaceutical industry is experiencing increased volatility, requiring attention to market dynamics. Amgen up 0.39%. Based on recent key news: 1. On August 11, BeiGene's collaboration with Amgen on the drug Antisense officially entered clinical use, covering medical institutions in multiple cities nationwide. This move is expected to improve treatment options for extensive-stage small cell lung cancer patients, driving Amgen's stock price up. Source: Viewpoint Network 2. On August 10, Amgen launched multiple clinical projects for MariTide, covering areas such as obesity and diabetes. Its extended dosing frequency has improved patient compliance and enhanced market competitiveness, supporting the stock price increase. Source: Zhitong Finance 3. On August 12, Amgen's annualized return over the past 15 years was 14.88%, indicating long-term investment value and attracting investor attention. Source: Benzinga Biotech industry innovation in drug development is active. **Stocks with High Market Capitalization in the Industry** Forte Pharmaceuticals down 0.79%. Based on recent key news: 1. On August 11, Sionna Therapeutics' cystic fibrosis treatment failed, causing its stock price to plummet by 92%. This event significantly boosted Vertex Pharmaceuticals' stock price, alleviating ongoing pressure on its shares 2. On August 10, Sionna Therapeutics announced that its experimental drug SION-719 failed to improve sweat chloride levels in the mid-stage study, leading to a significant drop in stock price and affecting market sentiment. 3. On August 11, analysts raised the target price for Vertex Pharmaceuticals to $633, reflecting increased market confidence in its competitive advantages. The biotechnology industry has seen increased volatility recently and requires attention ### Related Stocks - [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Pyxis Oncology posts corporate deck spotlighting MICVO extracellular-targeting ADC in head-and-neck cancer](https://longbridge.com/en/news/295788544.md) - [GSA Capital Partners LLP Takes Position in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296193567.md) - [Grandfield & Dodd LLC Makes New Investment in Gilead Sciences, Inc. $GILD](https://longbridge.com/en/news/296196164.md) - [B. Metzler seel. Sohn & Co. AG Cuts Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/296578862.md) - [Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/296462167.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**